OAM
ONC

Oppenheimer Asset Management’s BeOne Medicines Ltd ONC Stock Holding History

Oppenheimer Asset Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.66M Buy
32,532
+2,443
+8% +$791K 0.11% 210
2025
Q4 		$9.14M Sell
30,089
-1,585
-5% -$519K 0.11% 207
2025
Q3 		$10.8M Buy
31,674
+2,137
+7% +$649K 0.12% 194
2025
Q2 		$7.15M Sell
29,537
-622
-2% -$153K 0.08% 267
2025
Q1 		$8.21M Sell
30,159
-786
-3% -$184K 0.1% 223
2024
Q4 		$5.72M Buy
30,945
+518
+2% +$106K 0.07% 299
2024
Q3 		$6.83M Buy
30,427
+3,503
+13% +$630K 0.08% 261
2024
Q2 		$3.84M Buy
26,924
+8,800
+49% +$1.36M 0.05% 369
2024
Q1 		$2.83M Buy
18,124
+1,507
+9% +$243K 0.04% 400
2023
Q4 		$3M Buy
16,617
+2,816
+20% +$509K 0.04% 411
2023
Q3 		$2.48M Buy
13,801
+1,986
+17% +$393K 0.04% 422
2023
Q2 		$2.11M Buy
11,815
+430
+4% +$99K 0.03% 495
2023
Q1 		$2.45M Buy
11,385
+97
+0.9% +$23.3K 0.04% 439
2022
Q4 		$2.48M Sell
11,288
-653
-5% -$120K 0.04% 423
2022
Q3 		$1.61M Sell
11,941
-262
-2% -$45K 0.03% 510
2022
Q2 		$1.98M Buy
12,203
+256
+2% +$40K 0.03% 468
2022
Q1 		$2.25M Sell
11,947
-1,291
-10% -$274K 0.03% 498
2021
Q4 		$3.59M Buy
13,238
+259
+2% +$87.4K 0.05% 381
2021
Q3 		$4.71M Buy
12,979
+7
+0.1% +$2.29K 0.07% 313
2021
Q2 		$4.45M Buy
12,972
+539
+4% +$179K 0.06% 324
2021
Q1 		$4.33M Sell
12,433
-947
-7% -$314K 0.07% 316
2020
Q4 		$3.46M Buy
13,380
+427
+3% +$118K 0.06% 349
2020
Q3 		$3.71M Buy
12,953
+504
+4% +$118K 0.07% 300
2020
Q2 		$2.35M Buy
12,449
+122
+1% +$19.9K 0.05% 368
2020
Q1 		$1.52M Buy
12,327
+10,660
+639% +$1.67M 0.04% 409
2019
Q4 		$276K Sell
1,667
-261
-14% -$43.4K 0.01% 980
2019
Q3 		$236K Sell
1,928
-49
-2% -$6.51K 0.01% 1003
2019
Q2 		$245K Sell
1,977
-309
-14% -$39.2K 0.01% 1001
2019
Q1 		$302K Sell
2,286
-559
-20% -$75.4K 0.01% 938
2018
Q4 		$399K Sell
2,845
-3
-0.1% -$398 0.01% 824
2018
Q3 		$490K Buy
+2,848
New +$479K 0.01% 814

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Oppenheimer Asset Management's ONC Position: Q1 2026 in Review

Oppenheimer Asset Management increased its BeOne Medicines Ltd (ONC) stake by 8.1% in Q1 2026, buying an estimated $791K and bringing the position to 32,532 shares worth $9.66M. The position accounts for 0.11% of the portfolio, ranked #210.

Oppenheimer Asset Management first reported a position in ONC in Q3 2018 and has held it in 31 quarters since. The position peaked at $10.8M in Q3 2025. 282 funds tracked by Wall St. Rank hold ONC as of Q1 2026.

  • Oppenheimer Asset Management held 32,532 shares of BeOne Medicines Ltd worth $9.66M as of Q1 2026.
  • Oppenheimer Asset Management bought 2,443 BeOne Medicines Ltd shares in Q1 2026, an estimated $791K.
  • BeOne Medicines Ltd made up 0.11% of Oppenheimer Asset Management's portfolio in Q1 2026, its #210 holding.
  • Oppenheimer Asset Management first reported a position in BeOne Medicines Ltd in Q3 2018 and has held it in 31 quarters since.
  • Oppenheimer Asset Management's BeOne Medicines Ltd position peaked at $10.8M in Q3 2025.
  • 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.

Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.